Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

97.70 -1.30 (-1.31%)
Official Closing Price Updated: 7:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30
From Glaukos Corporation
Via Business Wire
Glaukos Announces EU MDR Certification for iStent infinite® and Other Leading MIGS Therapies
From Glaukos Corporation
Via Business Wire
Glaukos to Celebrate 10th Anniversary of IPO Listing with NYSE Closing Bell
From Glaukos Corporation
Via Business Wire
Earnings Scheduled For April 30, 2025
Via Benzinga
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today
Via Benzinga
Earnings Scheduled For February 20, 2025
Via Benzinga
Peering Into Glaukos's Recent Short Interest
Via Benzinga
Glaukos Announces Participation in Upcoming Investor Conferences
From Glaukos Corporation
Via Business Wire
What 11 Analyst Ratings Have To Say About Glaukos
Via Benzinga
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
Via Benzinga
Glaukos Announces First Quarter 2025 Financial Results
From Glaukos Corporation
Via Business Wire
How Is The Market Feeling About Glaukos?
Via Benzinga
$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today
Via Benzinga
What 11 Analyst Ratings Have To Say About Glaukos
Via Benzinga
Glaukos to Present Multiple Scientific Abstracts at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
From Glaukos Corporation
Via Business Wire
Forecasting The Future: 7 Analyst Projections For Glaukos
Via Benzinga
Glaukos Announces the Release of its 2024 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30
From Glaukos Corporation
Via Business Wire
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years
Via Benzinga
RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution
From Glaukos Corporation
Via Business Wire
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery
Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential. 
Via Benzinga
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
From Glaukos Corporation
Via Business Wire
Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday?
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.  
Via Benzinga
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition
Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model. 
Via Benzinga
Wondering what's happening in today's after-hours session?
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results
From Glaukos Corporation
Via Business Wire
This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20
From Glaukos Corporation
Via Business Wire
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
From Glaukos Corporation
Via Business Wire
Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market
TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation. 
Via Benzinga
Topics Fraud
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.